These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30922116)

  • 21. Bayesian hidden Markov models for delineating the pathology of Alzheimer's disease.
    Kang K; Cai J; Song X; Zhu H
    Stat Methods Med Res; 2019 Jul; 28(7):2112-2124. PubMed ID: 29278101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychotherapeutic interventions in individuals at risk for Alzheimer's dementia: a systematic review.
    Rostamzadeh A; Kahlert A; Kalthegener F; Jessen F
    Alzheimers Res Ther; 2022 Jan; 14(1):18. PubMed ID: 35101105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials.
    Verma N; Beretvas SN; Pascual B; Masdeu JC; Markey MK;
    Curr Alzheimer Res; 2018 Mar; 15(5):429-442. PubMed ID: 29110613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Zhang S; Smailagic N; Hyde C; Noel-Storr AH; Takwoingi Y; McShane R; Feng J
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010386. PubMed ID: 25052054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A selenium species in cerebrospinal fluid predicts conversion to Alzheimer's dementia in persons with mild cognitive impairment.
    Vinceti M; Chiari A; Eichmüller M; Rothman KJ; Filippini T; Malagoli C; Weuve J; Tondelli M; Zamboni G; Nichelli PF; Michalke B
    Alzheimers Res Ther; 2017 Dec; 9(1):100. PubMed ID: 29258624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression.
    Rajji TK; Bowie CR; Herrmann N; Pollock BG; Bikson M; Blumberger DM; Butters MA; Daskalakis ZJ; Fischer CE; Flint AJ; Golas AC; Graff-Guerrero A; Kumar S; Lourenco L; Mah L; Ovaysikia S; Thorpe KE; Voineskos AN; Mulsant BH;
    J Alzheimers Dis; 2020; 76(2):733-751. PubMed ID: 32568198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.
    Schneider LS; Bennett DA; Farlow MR; Peskind ER; Raskind MA; Sano M; Stern Y; Haneline S; Welsh-Bohmer KA; O'Neil J; Walter R; Maresca S; Culp M; Alexander R; Saunders AM; Burns DK; Chiang C
    J Prev Alzheimers Dis; 2022; 9(4):625-634. PubMed ID: 36281666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS.
    Rosenberg A; Mangialasche F; Ngandu T; Solomon A; Kivipelto M
    J Prev Alzheimers Dis; 2020; 7(1):29-36. PubMed ID: 32010923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Green Tea Intake and Risks for Dementia, Alzheimer's Disease, Mild Cognitive Impairment, and Cognitive Impairment: A Systematic Review.
    Kakutani S; Watanabe H; Murayama N
    Nutrients; 2019 May; 11(5):. PubMed ID: 31137655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0.
    Ritchie CW; Muniz-Terrera G; Kivipelto M; Solomon A; Tom B; Molinuevo JL
    J Prev Alzheimers Dis; 2020; 7(1):8-13. PubMed ID: 32010920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
    Langbaum JB; Ellison NN; Caputo A; Thomas RG; Langlois C; Riviere ME; Graf A; Lopez Lopez C; Reiman EM; Tariot PN; Hendrix SB
    Alzheimers Res Ther; 2020 May; 12(1):66. PubMed ID: 32460855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin E for Alzheimer's disease and mild cognitive impairment.
    Isaac MG; Quinn R; Tabet N
    Cochrane Database Syst Rev; 2008 Jul; (3):CD002854. PubMed ID: 18646084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.
    Clare L; Kudlicka A; Oyebode JR; Jones RW; Bayer A; Leroi I; Kopelman M; James IA; Culverwell A; Pool J; Brand A; Henderson C; Hoare Z; Knapp M; Morgan-Trimmer S; Burns A; Corbett A; Whitaker R; Woods B
    Health Technol Assess; 2019 Mar; 23(10):1-242. PubMed ID: 30879470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.